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Although it is sometimes stated that the brain
is unique among tissues in its high rate of oxidative metabolism, the overall cerebral metabolic rate for Oz (CMROz) is of the same order
as the unstressed heart and renal cortex [1]. Regional metabolic fluxes in brain may greatly exceed CMROz, however, and these are closely
coupled to fluctuations in metabolic demand.
(Alterations in energy and carbohydrate metabolism, which are produced by varying functional demands of the nervous system and by
pathological conditions, are discussed in Chapters 29, 39, 40, and 41. Peripheral nerve metabolism is discussed in Chap. 35 .)

faster [2]. The level of ,. . . P is kept constant by
regulation of ADP phosphorylation in relation
to ATP hydrolysis. The active adenylate kinase
reaction, which forms equal amounts of ATP
and AMP from ADP, prevents any great accumulation of ADP. Only a small amount of
AMP is present under steady-state conditions;
consequently, a relatively small percentage decrease in ATP may lead to a relatively large percentage increase in AMP. Since AMP is a positive modulator of several reactions that lead to
increased ATP synthesis, such an amplification
factor provides a sensitive control for maintenance of ATP levels [3]. Between 37° and 42°C,
brain metabolic rate increases at a rate of approximately 5 percent per degree.
The level of creatine phosphate in brain is
even higher than that of ATP, and creatine phosphokinase is extremely active. The creatine
phosphate level is exquisitely sensitive to
changes in oxygenation, providing ,. . . P for ADP
phosphorylation and thus maintaining ATP levels. The creatine phosphokinase system may
also function in regulating mitochondrial activity. Shuttling high-energy phosphate produced
by mitochondria to sites of utilization, such as
membrane ATPase and axonal transport sites,
in the form of creatine phosphate rather than
ATP, sustains the ADP level and stimulates mitochondrial activity. In cells with a very heterogeneous mitochondrial distribution, such as
neurons, the creatine phosphate shuttle may
play a critical role in energy transport [4]. The
BB isoenzyme of creatine kinase is characteristic of, but not confined to, brain. Thus, the
presence of BB in body fluids does not necessarily indicate disruption of neural tissue.

ENERGY METABOLISM
A TP production in brain is highly
regulated
Oxidative steps of carbohydrate metabolism
normally contribute 36 of the 38 high-energy
phosphate bonds (,...... P) generated during the
aerobic metabolism of a single glucose molecule. Approximately 15 percent of brain glucose
is converted to lactate and does not enter the
Krebs (citric acid) cycle. There are indications,
however, that this might be matched by a corresponding uptake of ketone bodies. The total
net gain of high energy phosphate (,...... P) is 33
equivalents per mole of glucose utilized. The
steady-state level of ATP is high and represents
the sum of very rapid synthesis and utilization.
On average, half the terminal phosphate groups
of ATP turn over in approximately 3 sec; in certain regions, turnover is probably considerably
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Under ordinary conditions, the basic
substrate for brain metabolism is
glucose

•

..

The brain depends on glucose for energy and as
the major carbon source for a wide variety of
simple and complex molecules. Although other
tissues can utilize glucose, it is not the primary
metabolite of most. Heart, renal cortex, and
even liver (the carbohydrate storehouse) derive
most of their energy from fatty acids. During
hypoglycemia these other tissues stop metabolizing glucose, making more available to the
brain. Liver glycogen metabolism is under
neural as well as hormonal control, allowing a
sensitive response to the needs of the brain.
Stimulation of a cholinergic pathway in the lateral hypothalamus causes increased liver glycogen synthesis and decreased gluconeogenesis
(through the vagus nerve), and stimulation of
the ventromedial hypothalamus causes increased glycogenolysis and gluconeogenesis by
a process not mediated by cyclic AMP (cAMP).
A transient decline in the oxidative metabolism of glucose may lead to an abrupt disruption of brain function. Despite this dependence
on glucose, the brain at rest extracts only approximately 10 percent of the glucose from the
blood flowing through it [---5 mg (28 1-1mol) glucose/100 g/min]. If blood flow slows down, the
brain takes up a relatively greater fraction of
both the oxygen and glucose present in blood
(see Chap. 29). The entry of most water-soluble
substances into brain from blood is restricted.
Specific mechanisms do exist, however, to
carry certain important metabolites across the
blood-brain barrier (BBB) (see Chap. 30). Many
glycolytic metabolites, and substances that can
be transformed into these metabolites, can sustain brain metabolism in vitro, but they fail to
do so in the intact animal because they cannot
penetrate into brain at sufficient rates. Although
mannose may sustain brain metabolism in vivo,
most other sugars, such as fructose, cannot be
taken up rapidly enough to support brain me-
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tabolism. Fructose can in fact sustain metabolism in the immature brain, but this may be related to an incomplete BBB or to a lower
metabolic demand before the brain matures.
Glucose crosses the BBB by a carrier
mechanism (see Chap. 30) that regulates the rate
of glucose entry into brain and helps to maintain
the concentration of glucose lower in brain than
in structures lacking this barrier, for example,
sympathetic ganglia or peripheral nerve terminals [5]. The regulation of entry is governed by
the Michaelis constant (Km) of glucose uptake
which is 7 to 8 mM in mammalian brain, approximately the level of plasma glucose. With
a concentration at or below the Km of the system, small changes in plasma glucose cause significant changes in the amount transported.
Thus, within limits, glucose and glycogen levels
in brain vary directly with blood glucose concentrations. The rate of influx of glucose increases linearly to approximately 7 mM plasma
glucose and at a lower rate to approximately 20
mM. Brain glucose is always lower than blood
glucose. There is, then, no safety device to supplement such a small carbohydrate reserve during hypoglycemia.
Beyond the BBB, brain cells take up glucose much more avidly. Glucose can be taken
up into nerve terminals by carrier processes that
possess an affinity for glucose 30 times higher
than that of the BBB. These terminals may be
able to function despite low overall brain glucose levels. Brain tissue beyond the BBB is apparently sensitive to insulin, and an increase in
glucose uptake and glycogen storage by insulin
can be demonstrated in vitro. Although at
present there is no report of a definite effect of
circulating insulin on the intact brain, insulin
has been detected in cerebrospinal fluid (CSF).
Insulin receptors are present in brain, and the
metabolism of isolated brain tissue can be affected by insulin; however, the significance of
these effects is unknown.
Although brain glucose levels vary (within
limits) with plasma levels, the affinity of hex-
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okinase for glucose is much greater than the apparent affinity of the capillary transport system,
and under normal conditions glycolysis is regulated by hexokinase activity and not by glucose transport into brain [6]. Regionally, the influx may be independent of local glycolytic
rates; for example, the cerebellum has a higher
influx rate than cerebral cortex despite having
a lower glycolytic rate.
In this respect brain differs from other tissues in which various insulin-dependent and insulin-independent transport systems modify
glycolytic flux. Glucose influx becomes important under conditions of increased den1and,
such as seizures, or hypoglycemia (<50 mg/1 00
ml plasma glucose).
Brain also differs from other tissues by actually decreasing rather than increasing glucose
transport across the BBB during hypoxia, perhaps an adjustment to prevent accumulation of
potentially toxic lactate (see also Chap. 40). In
contrast, heart and skeletal muscle, which increase glucose transport during hypoxia, have
a much greater lactate efflux and accumulate
much less lactate than brain. The low lactate
transport capacity may be an adaptation to protect brain from the high plasma lactate levels
that occur during strenuous exercise. Brain lactate effiux is more rapid in the neonate, possibly
contributing to the resistance of neonatal brain
to anoxia [6].

Glycogen is a dynamic, but limited,
energy store
Although present in relatively low concentrations in brain (3.3 mmol/kg brain in rat), glycogen is a unique energy reserve that requires
no energy (ATP) for initiation of its metabolism.
As with glucose, glycogen levels in brain appear
to vary with plasma glucose concentrations.
Brain biopsies have shown that human brain
contains much higher glycogen levels than rodent brain, but the effects of anesthesia and
pathological changes in the biopsied tissue may

have contributed to these high levels. Glycogen
granules have been seen in electron micrographs of glia and neurons of immature animals
but only in astrocytes of adults. Barbiturates
decrease brain metabolism and increase the
number of granules seen, particularly in astrocytes of synaptic regions; however, biochemical
studies show that neurons do contain glycogen
and that the enzymes for its synthesis and metabolism are present in synaptosomes. Astrocyte glycogen may form a store of carbohydrate
made available to neurons by still undefined
mechanisms. Associated with the granules are
enzymes concerned with glycogen synthesis
and, perhaps, degradation. The increased glycogen found in areas of brain injury may be due
to glial changes or to decreased utilization during tissue preparation.
The accepted role of glycogen is that of a
carbohydrate reserve utilized when glucose
falls below need. However, there is a rapid,
continual breakdown and synthesis of glycogen
(19 1-1mollkg/min). This is approximately 2 percent of the normal glycolytic flux in brain and
is subject to elaborate control mechanisms. This
suggests that, even under steady-state conditions, local carbohydrate reserves are important
for brain function. If glycogen were the sole supply, however, the normal glycolytic flux in brain
would be maintained for less than 5 min.
The enzyme systems that synthesize and
catabolize glycogen in other tissues are also
found in brain, but their kinetic properties and
modes of regulation appear to differ [7]. Glycogen metabolism in brain, unlike in other tissues, is controlled locally. It is isolated from the
tumult of systemic activity, evidently because
of the blood-brain barrier. Although glucocorticoid hormones that penetrate the BBB increase glycogen turnover, circulating protein
hormones and biogenic amines are without effect. Beyond the BBB, cells are sensitive to
local amine levels; drugs that penetrate the BBB
and modify local amine levels or membrane receptors thus cause metabolic changes.

•
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Separate systems for the synthesis and degradation of glycogen provide a greater degree
of control than would be the case were glycogen
degraded by simply reversing the steps in its
synthesis (Fig. 1). The level of glucose-6-phosphate, the initial synthetic substrate, usually varies inversely with the rate of brain glycolysis
because of a greater facilitation of the phosphofructokinase step relative to glucose transport and phosphorylation. Thus, a decline in
glucose-6-phosphate at times of energy need decreases glycogen formation.
The glucosyl group of UDP is transferred
to the terminal glucose of the nonreducing end
of an amylose chain in an a-1 ,4-glycosidic linkage (Fig. 1). This reaction is catalyzed by glycogen synthetase and is the rate-controlling reaction in glycogen synthesis [7]. In brain, as in
other tissues, glycogen synthetase occurs in
both a phosphorylated (D) form, which is dependent for activity on glucose-6-phosphate as

a positive modulator, and as a dephosphorylated, independent (I) form sensitive to, but not
dependent on, the modulator. Although in brain
the independent form of the glycogen synthetase requires no stimulator, it has a relatively
low affinity for UDP glucose. At times of increased energy demand, not only is there a
change from the dependent to the independent
form, but also an independent form with an even
lower affinity for the substrate develops. The
inhibition of glycogen synthesis is enhanced,
and this increases the availability of glucose-6phosphate for energy needs. Goldberg and
O'Toole [7] hypothesize that the independent
form in brain is associated with inhibition of glycogen synthesis under conditions of energy demand, whereas the dependent form is responsible for a relatively small regulated synthesis
under resting conditions. Regulation of the dependent form may be responsible for reducing
the rate of glycogen formation in brain to ap-
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FIG. 1. Glycogen metabolism in brain. Enzyme data from mouse brain homogenates: numerals below each
enzyme represent V max at 38°C (in mmollkg wet weight/min); metabolite levels from quick-frozen adult mouse
brain in ,_,..mol/kg wet weight; (P) phosphate. (Metabolic data from J. V. Passonneau et al., J. Bioi. Chern.
244:902, 1969; enzyme data from B. M. Breckenridge and P. D. Gatfield , J. Neurochem. 3:234, 1961.)
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proximately 5 percent of its potential rate. In
liver, where large amounts of glycogen are synthesized and degraded, the independent form of
the synthetase is associated with glycogen formation. At the present time, it appears that the
two tissues use the same biochemical apparatus
in different ways in relation to differences in
overall metabolic patterns.
Under steady-state conditions, it is probable that less than 10 percent of phosphorylase
in brain (Fig. 1) is in the unphosphorylated b
form (requiring AMP), which is inactive at the
very low AMP concentrations present normally. When the steady state is disturbed, there
may be an extremely rapid conversion of the
enzyme to the a form, which is active at low
AMP levels. Brain phosphorylase b kinase is
indirectly activated by cAMP and by the micromolar levels of Ca2 + released during neuronal excitation (see Chaps. 17 and 18). Endoplasmic reticulum of brain, like that in muscle,
is capable of taking up Ca2 + to terminate its
stimulatory effect. These reactions provide energy from glycogen during excitation and when
cAMP-forming systems are activated. It has not
been possible to confirm directly, however, that
the conversion from phosphorylase b to a is a
control point of glycogenolysis in vivo. Norepinephrine and, probably, dopamine activate
glycogenolysis through cAMP; but epinephrine,
vasopressin, and angiotensin II do so by another
mechanism, possibly involving Ca2 + or a Ca2 + mediated proteolysis of the phosphorylase kinase.
Hydrolysis of the a-1 ,4-glycoside linkages
leaves a limit dextrin that turns over at only half
the rate of the outer chains (see also Chap. 33).
The debrancher enzyme that hydrolyzes the a1,6-glycoside linkages may be rate limiting if the
entire glycogen granule is to be utilized. Because one product of this enzyme is free glucose, approximately one glucose molecule for
every eleven of glucose-6-phosphate is released
if the entire glycogen molecule is degraded (Fig.
1). a-Glucosidase (acid maltase) is a lysosomal

enzyme whose precise function in glycogen metabolism is not known. In Pompe' s disease (the
hereditary absence of a-glucosidase), glycogen
accumulates in lysosomes in brain as well as in
those elsewhere (Chaps. 33 and 37). The steadystate level of glycogen is regulated precisely by
the coordination of synthetic and degradative
processes through enzymatic regulation at several metabolic steps [8].

Brain glycolysis is regulated mainly by
hexokinase and phosphofructokinase
Aerobic and anaerobic glycolysis have been historically defined as the amount of lactate produced under conditions of " adequate" oxygen
and no oxygen, respectively. More recently ,
glycolysis refers to the Embden-Meyerhof glycolytic sequence from glucose (or glycogen glucosyl) to pyruvate. Glycolytic flux is defined
indirectly-it is the rate at which glucose must
be utilized to produce the observed rates of
ADP phosphorylation.
Figure 2 outlines the flow of glycolytic substrates in brain. Glycolysis first involves phosphorylation by hexokinase. The reaction is essentially irreversible and is a key point in the
regulation of carbohydrate metabolism in brain.
The electrophoretically slow-moving (type 1)
isoenzyme of hexokinase is characteristic of
brain. In most tissues , hexokinase may exist in
the cytosol (soluble) , or it may be firmly attached to mitochondria. Under conditions in
which no special effort is made to stop metabolism while' isolating mitochondria, 80 to 90 percent of brain hexokinase is bound. In the live
steady state, however, when availability of substrates keeps up with metabolic demand and end
products are removed, an equilibrium exists between the soluble and the bound enzyme. Binding changes the kinetic properties of hexokinase
and its inhibition by glucose-6-phosphate, so
that the bound enzyme on mitochondria is more
active. The extent of binding is inversely related
to the ATP/ADP ratio , so that conditions in

•
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FIG. 2. Glycolysis in brain. Enzyme and metabolic data expressed as in Fig. 1; (*) 10-day-old mouse brain
(Matchinski, 1970). (Data from H. Mcilwain, Biochemistry and the Central Nervous System. Boston: Little,
Brown, 1966, pp. 1-26. F. M. Matchinski, Adv. Biochem. Psychopharmacol. 2:217-243, 1970.)

which energy utilization exceeds supply shift
the solubilization equilibrium to the bound form
and produce a greater potential capacity for initiating glycolysis to meet the energy demand.
This mechanism allows ATP to function both as
a substrate of the enzyme and, at another site,
as a regulator to decrease ATP production
through its influence on enzyme binding. It also
confers preference on glucose in the competition for the MgATP2 - generated by mitochondrial oxidative phosphorylation. Thus, a pro-

cess that will sustain ATP production continues
at the expense of other uses of energy. Because
energy reserves are rapidly exhausted postmortem, it is not surprising that brain hexokinase is found to be almost entirely bound.
The significance of reversible binding of
other enzymes to mitochondria is not clear. The
measured glycolytic flux, when compared with
the maximal velocity of hexokinase, indicates
that, in the steady state, the hexokinase reaction
is 97 percent inhibited. Brain hexokinase is in-
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hibited by its product, glucose-6-phosphate, and
to a lesser extent by ADP and allosterically by
3-phosphoglycerate and several nucleoside
phosphates, including cAMP and free ATP4-.
The ratio of ATP to Mg2 + may also have a regulatory action. In addition to acting on enzyme
kinetics, glucose-6-phosphate solubilizes hexokinase, thus reducing the enzyme's efficiency
when the reaction product accumulates. The
sum total of these mechanisms is a fine tuning
of the activity of the initial enzyme of glycolysis
in response to changes in the cellular environment. Glucokinase (low-affinity hexokinase), a
major component of liver hexokinase, has not
been found in brain.
Glucose-6-phosphate represents a branch
point in metabolism because it is a common substrate for enzymes involved in glycolytic, pentose phosphate shunt, and glycogen-forming
pathways. There is also slight, but detectable,
glucose-6-phosphatase activity in brain, the significance of which is not clear. The liver requires this enzyme to convert glycogen to glucose. The differences between liver and brain
hexokinase and the differences between the
modes of glycogen metabolism of these two tissues can be related to the function of liver as a
carbohydrate storehouse for the body, whereas
brain metabolism is adapted for rapid carbohydrate utilization for energy needs.
In glycolysis, glucose-6-phosphate is the
substrate of phosphohexose isomerase. This is
a reversible reaction (small free-energy change)
whose 5: 1 equilibrium ratio in brain favors glucose-6-phosphate.
Fructose-6-phosphate is the substrate of
phosphofructokinase, a key regulatory enzyme
controlling glycolysis [3]. The other substrate is
MgATP2 - • Like other regulatory reactions, it
is essentially irreversible. It is modulated by a
large number of metabolites and cofactors
whose concentrations under different metabolic
conditions have a great effect on glycolytic flux.
Prominent among these are availability of . . . , P
and citrate levels. Brain phosphofructokinase is

inhibited by ATP, Mg2 +, and citrate and is stimulated by NH4+, K+, P04 3 - , 5'-AMP, 3',5'cyclic AMP, ADP, and fructose-1 ,6-bisphosphate.
When oxygen is admitted to cells metabolizing anaerobically, utilization of 02 increases, whereas utilization of glucose and production of lactate drop (Pasteur effect).
Modulation of the phosphofructokinase reaction can account directly for the Pasteur effect.
In the steady state, ATP and citrate levels in
brain apparently are sufficient to keep phosphofructokinase relatively inhibited as long as
the level of positive modulators (or disinhibitors) is low. When the steady state is disturbed,
activation of this enzyme produces an increase
in glycolytic flux that takes place almost as fast
as the events changing the internal milieu.
Fructose-1 ,6-bisphosphate is split by brain
aldolase to glyceraldehyde-3-phosphate and
dihydroxyacetone phosphate. Dihydroxyacetone phosphate is the common substrate for
both glycerophosphate dehydrogenase, an enzyme active in N ADH oxidation and lipid pathways (see Chap. 5), and triose phosphate isomerase, which maintains an equilibrium
between dihydroxyacetone phosphate and glyceraldehyde-3-phosphate; the equilibrium
strongly favors accumulation of dihydroxyacetone phosphate.
After the reaction with glyceraldehyde
phosphate dehydrogenase, glycolysis in the
brain proceeds through the usual steps. Brain
enolase (n-2-phosphoglycerate hydrolase),
which catalyzes dehydration of 2-phosphoglycerate to phosphoenolpyruvate, is present as
two related dimers, one of which ('Y) is specifically associated with neurons and the other (a)
with glia. The neuronal subunit is identical to
the neuron-specific protein 14-3-2. Immunochemical determination of the enolases makes
them useful in determining neuron/glia ratios in
tissue samples, but neuron-specific enolase is
not confined to neural tissue. Brain phosphoenolpyruvate kinase controls an essentially irre-
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versible reaction that requires not only Mg2+
(as do several other glycolytic enzymes) but
also K + or N a+. This step also may be regulatory.
Brain tissue, even when it is at rest and well
oxygenated, produces a small amount of lactate, which is removed in the venous blood, accounting for 13 percent of the pyruvate produced by glycolysis. The measured lactate level
in brain depends on the success in rapidly arresting brain metabolism prior to tissue processing. Five lactate dehydrogenase isoenzymes are present in adult brain, of which the
one that moves electrophoretically most rapidly
toward the anode (band 1) predominates. This
isoenzyme is generally higher in those tissues
that are more dependent on aerobic processes
for energy; the slower moving isoenzymes are
relatively higher in tissues such as white skeletal
muscle, which is better adapted to function at
suboptimal oxygen levels (see Chap. 31). The
distribution of lactate dehydrogenase isoenzymes in various brain regions, layers of the
retina, brain neoplasms, and brain tissue cultures and during development indicates that
their synthesis might be controlled by tissue oxygen levels. Lactate dehydrogenase functions in
the cytoplasm as a means of oxidizing NADH,
which accumulates as the result of the activity
of glyceraldehyde phosphate dehydrogenase in
glycolysis. It thus permits glycolytic ATP production to continue under anaerobic conditions.
Lactate dehydrogenase also functions under
aerobic conditions because N ADH cannot easily penetrate the mitochondrial membrane. The
oxidation of NADH in the cytoplasm depends
on this reaction and on the activity of shuttle
mechanisms that transfer reducing equivalents
to the mitochondria.
Glycerol phosphate dehydrogenase is another enzyme indirectly associated with glycolysis that participates in the cytoplasmic oxidation of NADH. This enzyme reduces
dihydroxyacetone phosphate to glycerol-3phosphate, oxidizing NADH in the process.
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Under hypoxic conditions, levels of a-glycerophosphate and lactate increase initially at comparable rates, although the amount of lactate
produced greatly exceeds that of a-glycerophosphate. The relative levels of the oxidized
and reduced substrates of these reactions indicate much higher local levels of N AD H in
brain than are found by gross measurements. In
fact, the relative proportions of oxidized and
reduced substrates of the reactions that are
linked to the pyridine nucleotides may be a better indicator of local oxidation-reduction states
(NAD +/NADH) in brain than is provided by the
direct measurement of the pyridine nucleotides
themselves [3,5].
An aspect of glucose metabolism that has
led to much confusion among neurochemists is
the observation that labeled glucose appears in
carbon dioxide much more slowly than might
be suggested from a cursory examination of the
glycolytic pathway plus the citric acid cycle
[10]. Glucose flux is 0.5 to 1.0 ~moVmin/g wet
weight of brain in a variety of species. The level
of glycolytic plus Krebs cycle intermediates is
2 ~moVg. Hence, these intermediates might be
predicted to turn over every 2 to 4 min, and
14
C02 production might be predicted to reach a
steady state in 5 to 10 min. This is not observed
experimentally. In addition, large quantities of
radioactivity are trapped in amino acids related
to the Krebs cycle (70-80 percent) from 10 to
30 min after a glucose injection. This is due to
the high activity of transaminase in comparison
with the flux through the Krebs cycle, and the
amino acids developed by transamination behave as if they were a part of the cycle. When
the pools of these amino acids (.--..20 ~moVg) are
added to the levels of Krebs cycle components
plus glycolytic intermediates, the calculated
time for 14C02 evolution is increased by a factor
of 10, which agrees with the values observed
experimentally.
In contrast, in tissues such as liver, the
amino acids related to the Krebs cycle are
present at much lower steady-state values, and
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20 percent of the radioactivity from administered glucose is trapped in these amino acids at
short times after injection. As a result, ignoring
the radioactivity trapped in amino acids has a
relatively small effect on estimates of glycolytic
fluxes in liver but makes an enormous difference in brain. Immature brains more nearly resemble liver in this respect. The relationship of
the Krebs cycle to glycolysis undergoes a sharp
change during development, coincident with the
development of the metabolic compartmentation of amino acid metabolism characteristic of
adult brain.

The pyruvate dehydrogenase complex
plays a key role in regulating oxidation
Pyruvate dehydrogenase (14 nmol/minlmg protein in rat brain), which controls the entry of
pyruvate into the Krebs cycle as acetyl coenzyme A (acetyl-CoA), is actually a mitochondrial multienzyme complex that includes the
enzymes pyruvate dehydrogenase (decarboxylase), lipoate acetyltransferase, and lipoamide
dehydrogenase; the coenzymes thiamine pyrophosphate, lipoic acid, CoA, and flavine; and
nicotinamide dinucleotides. It is inactivated by
being phosphorylated at the decarboxylase
moiety by a tightly bound MgATP2 - -dependent
protein kinase and activated by being dephosphorylated by a loosely bound Mg2 +- and Ca2 + dependent phosphatase. About half the brain
enzyme is usually active. Pyruvate protects the
complex against inactivation by inhibiting the
kinase. ADP is a competitive inhibitor of Mg2 +
for the inactivating kinase. Under conditions of
greater metabolic demand, increases in pyruvate and ADP and decreases in acetyl-CoA and
ATP make the complex more active. Pyruvate
dehydrogenase is inhibited by NADH, decreasing formation of acetyl-CoA during hypoxia and
allowing more pyruvate to be reduced by lactate
dehydrogenase, thus forming the NAD necessary to sustain glycolysis. Several investigators
have reported abnormalities of the complex

(particularly lipoamide dehydrogenase) in some
hereditary ataxias, but not all studies have confirmed these findings, and the relationship remains tenuous. Pyruvate dehydrogenase defects do occur in several of the mitochondrial
enzyme deficiency states (see below and Morgan-Hughes [9]). (These are also described in
Chap. 33.)
Although acetylcholine synthesis is normally controlled by the rate of choline uptake
and choline acetyltransferase activity (see
Chap. 10), the supply of acetyl-CoA can be limiting under adverse conditions. Choline uptake
is, however, independent of acetyl-CoA concentration. A cytoplasmic pyruvate dehydrogenase specifically associated with acetylcholine synthesis has been suggested. The
mitochondrial membrane is not permeable to
the acetyl-CoA produced within it, but there is
efflux of its condensation product, citrate. Acetyl-CoA can then be formed from citrate in the
cytosol by ATP citrate lyase. The acetyl moiety
of acetylcholine is formed in a compartment
with rapid glucose turnover, presumably the
synaptosome. The cytosol of cholinergic endings is rich in citrate lyase, and it is probable
that the citrate shuttles the acetyl-CoA from the
mitochondrial compartment. During hypoxia or
hypoglycemia, acetylcholine synthesis can be
inhibited by failure of the acetyl-CoA supply.

Energy output and oxygen consumption
in adult brain are associated with high
levels of enzyme activity in the Krebs
cycle
The actual flux through the Krebs cycle depends on glycolysis and acetyl-CoA production,
which can "push" the cycle, the possible control at several enzymatic steps of the cycle, and
the local ADP level, which is known to be a
prime activator of the mitochondrial respiration
to which the Krebs cycle is linked. The steadystate level of citrate in brain is about one-fifth
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that of glucose. This is relatively high compared
with levels of glycolytic intermediates or with
that of isocitrate.
As in other tissues, there are two isocitrate
dehydrogenases in brain. One is active primarily in the cytoplasm and requires nicotinamideadenine dinucleotide phosphate (NADP) as cofactor; the other, bound to mitochondria and
requiring N AD, is the enzyme that participates
in the citric acid cycle. TheN AD-linked enzyme
catalyzes an essentially irreversible reaction,
has allosteric properties, is inhibited by ATP
and NADH, and may be stimulated by ADP.
The function of cytoplasmic N ADP isocitrate
dehydrogenase is uncertain, but it has been postulated that it supplies NADPH necessary for
many reductive synthetic reactions. The relatively high activity of this enzyme in immature
brain and white matter is consistent with such
a role. a- Ketoglutarate dehydrogenase, which
oxidatively decarboxylates a-ketoglutarate, requires the same cofactors as does the pyruvate
decarboxylation step.
Succinate dehydrogenase, the enzyme that
catalyzes the oxidation of succinate to fumarate, is tightly bound to mitochondrial membrane. In brain, succinate dehydrogenase may
also have a regulatory role when the steady state
is disturbed. Isocitrate and succinate levels in
brain are little affected by changes in the flux
of the citric acid cycle as long as an adequate
glucose supply is available. The highly unfavorable free-energy change of the malate dehydrogenase reaction is overcome by the rapid
removal of oxaloacetate, which is maintained at
low concentrations under steady-state conditions by the condensation reaction with acetylCoA [8].
Malic dehydrogenase is one of several enzymes in the citric acid cycle that is present in
both cytoplasm and mitochondria. The function
of the cytoplasmic components of these enzyme
activities is not known, but they may assist in
the transfer of hydrogen from the cytoplasm
into mitochondria.
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The Krebs cycle functions as an oxidative
process for energy production and as a source
of various amino acids, for example, glutamate,
glutamine, -y-aminobutyric acid (GABA), aspartate, and asparagine. To export net amounts
of a-ketoglutarate or oxaloacetate from the
Krebs cycle, the supply of dicarboxylic acids
must be replenished. The major route for this
seems to be the fixation of C02 to pyruvate or
another substrate at this three-carbon level.
Thus, the rate of C0 2 fixation sets the upper
limit at which biosynthetic reactions can occur.
This has been estimated as approximately 0.15
JJ.mol/g wet weight brain/min in studies of acute
ammonia toxicity in cats, or approximately 10
percent of the flux through the citric acid cycle.
Liver, on the other hand, appears to have ten
times the capacity of brain for C0 2 fixation, as
is appropriate for an organ geared to making
large quantities of protein for export. In brain,
pyruvate carboxylase, which catalyzes C0 2 fixation, appears to be largely an astrocytic enzyme. Pyruvate dehydrogenase activity seems
to be the rate-limiting step for the entry of pyruvate into the Krebs cycle from glycolysis.

The pentose shunt (hexose
monophosphate) pathway is active in
brain
Under basal conditions at least 5 to 8 percent
of brain glucose is likely so metabolized in the
adult monkey, and 2.3 percent in the rat [10].
Both shunt enzymes and metabolic flux have
been found in isolated nerve endings. The pathway has relatively high activity in developing
brain, reaching a peak during myelination. Its
main contribution is probably to produce the
NADPH required for the reductive reactions
necessary for lipid synthesis (see Chap. 5).
Shunt enzymes and metabolic flux are found in
synaptosomes. Although the capacity of the
pathway (as determined using nonphysiological
electron acceptors) remains constant throughout the rat life span, activity with physiological
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acceptors could not be detected in middle-aged
(18 months) and older animals. It is possible that
the shunt serves as a reserve pathway for use
under such stresses as the need for increased
lipid synthesis, repair, or reduction of oxidative
toxins. The shunt pathway also provides pentose for nucleotide synthesis; however, only a
small fraction of the activity of this pathway
would be required. As with glycogen synthesis,
turnover in the pentose-phosphate pathway decreases under conditions of increased energy
need, for example, during and after high rates
of stimulation. Pentose phosphate flux apparently is regulated by the concentrations of glucose-6-phosphate, NADP, glyceraldehyde-3phosphate, and fructose-6-phosphate. Since
transketolase, one of the enzymes in this pathway, requires thiamine pyrophosphate as a cofactor, poor myelin maintenance in thiamine deficiency may reflect the failure of the pathway
to provide sufficient NADPH for lipid synthesis
[8].

Glutamate in brain is compartmented
into separate pools
These pools, which subserve different metabolic pathways for glutamate, equilibrate with
each other only slowly. This compartmentation is a vital factor in the separate regulation
of special functions of glutamate and GABA,
such as neurotransmission, and general functions, such as protein biosynthesis.
Glutamate metabolism in brain is characterized by the existence of at least two distinct
pools; in addition, the Krebs cycle intermediates associated with these pools are also distinctly compartmented. A mathematical model
to fit data from radiotracer experiments that require separate Krebs cycles to satisfy the hypotheses of compartmentation has been developed. A key assumption of the current models
is that GABA is metabolized at a site different

from its synthesis. The best fit of kinetic data
is obtained when glutamate from a small pool
that is actively converted to glutamine flows
back to a larger pool (8 ,....,mol/g) that is converted to GABA. Of possible relevance, it has
been shown that glutamic acid decarboxylase
(GAD) is localized at or near nerve terminals,
whereas GABA transaminase, the major degradative enzyme, is mitochondrial.
Evidence points to an inferred small pool
of glutamate (2 ,....,mol/g) as probably glial. Glutamate released from nerve endings appears to
be taken up by glia (and by presynaptic and
postsynaptic terminals, or both), converted to
glutamine, and recycled to glutamate and
GABA. Various estimates of the proportion of
glucose carbon that flows through the GABA
shunt (see Chap. 15) have been published, but
the most definitive experiments show the value
to be approximately 10 percent of the total glycolytic flux. Although this may seem small, that
portion of the Krebs cycle flux that is used for
energy production (ATP synthesis, maintenance of ionic gradients) does not require C02
fixation, but that portion used for biosynthesis
of amino acids does. By recycling the carbon
skeleton of some of the glutamate through glutamine and GABA to succinate, the need for
dicarboxylic acids to replenish intermediates of
the Krebs cycle is diminished when export of
a-ketoglutarate takes place.
It is difficult to get good estimates of the
extent of C02 fixation in brain, but estimates of
the maximum capability obtained under conditions of ammonia stress , when glutamine levels increase rapidly, suggest that C02 fixation
occurs at 0.15 ,....,mol/g/min (in cat) and 0.33
,....,mol/g/min (in rat); that is, at about the same
rate as for the GABA shunt.
For comparison, it should be pointed out
that only approximately 2 percent of the glucose
flux in whole brain goes toward lipid synthesis,
and approximately 0.3 percent is used for protein synthesis. Thus, turnover of neurotrans-
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mitter amino acids is a major biosynthetic effort
in brain.
Metabolic compartmentation of glutamate
is usually observed when ketogenic substrates
are administered to animals. It is interesting that
acetoacetate and ~-hydroxybutyrate do not
show this effect, apparently because ketone
bodies are a normal substrate for brain and are
taken up into all types of cells. Acetate and similar substances, which are not taken up into
brain efficiently, appear to be more readily
taken up or activated in glia, or both. This may
lead to the abnormal glutamate/glutamine ratio
that is observed. Similarly, metabolic inhibitors
like fluoroacetate appear to act selectively in
glia and produce their neurotoxic action without
marked inhibition of the overall Krebs cycle
flux in brain. This difference in behavior between acetate and glucose has led to the suggestion that acetate and fluoroacetate may be
useful markers for the study of glial metabolism
by the technique of autoradiography [11].
A nonuniform distribution of metabolites in
living systems is a widespread occurrence.
Steady-state levels of GABA are well documented as varying over a five-fold range in discrete brain regions (2-1 0 mM), and it has been
estimated that GABA may be as high as 50 mM
in nerve terminals. Observations in brain indicate the existence of pools with half-lives of
many hours for mixing, which is most unusual.
The discovery of subcellular morphological
compartmentation-different populations of
mitochondria in cerebral cortex that have distinctive enzyme complements-may provide a
somewhat better perspective by which to visualize such separation of metabolic function
. .
In addition to the phasic release of both excitatory and inhibitory transmitters, there may
be a continuous tonic release of GABA, dependent only on the activity of the enzyme responsible for its synthesis and independent of the
depolarization of the presynaptic membrane.
Such inhibitory neurons could act tonically by
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constantly maintaining an elevated threshold in
the excitatory neurons so that the latter would
start firing when a decrease occurred in the
continuous release of GABA acting on them.
This is consistent with a known correlation
between the inhibition of GAD and the appearance of convulsions after certain drug
treatments. GABA levels have been observed
to be depleted by some convulsant drugs and
elevated by others.
The sine qua non of brain metabolism is
its high rate of mitochondrial respiration

Brain mitochondria have an affinity for oxygen
several times that of liver mitochondria and also
react differently to osmolar changes both morphologically and biochemically. Because current methods of separating mitochondria from
other cell components depend on sedimentation
from homogenates, differences related to function and intracellular provenance are difficult to
define. Furthermore, mitochondrial size and
function do change during maturation. Therefore, functional heterogeneity among brain mitochondria may be related to their location in
perikarya, synaptosomes, or various glial cells.
Unexpectedly, the specific activities of mitochondrial energy and metabolic enzymes have
been found to be higher in nonsynaptosomal
than in synaptosomal mitochondria [12].
In the coupled, controlled state, the level
of mitochondrial function depends on local concentrations of ADP. The entry of ADP into mitochondria is restricted insofar as it must exchange with intramitochondrial ATP. The high
steady-state mitochondrial respiration in brain
is related to local availability of substrates and
the ratio of ADP to ATP. This may not be reflected in the average ratio of ADP to ATP in
whole brain, which is quite low. Brain mitochondria also differ from those in other tissues
because they contain higher concentrations of
certain ''nonmitochondrial'' enzymes. Brain
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hexokinase, creatine kinase, and perhaps lactic
dehydrogenase are partially mitochondrial.
Hexokinase and creatine kinase may function
to maintain local levels of ADP by transferring
,__ P from ATP to creatine or glucose [4].
Among the mitochondrial enzymes for
which genetic information is carried in the small
mitochondrial DNA complement are cytochrome C oxidase subunits I, II, and III and
ATPase subunit 6 [9]. Defects in either the mitochondrial or the chromosomally specified enzymes or in their transport could lead to physiological dysfunction. Tissues with high rates of
aerobic metabolism, such as brain, retina, and
cardiac and skeletal muscle, are particularly
vulnerable [9]. Several different clinical syndromes have been found to be due to defects in
Krebs cycle metabolism: ~-oxidase, carnitine
and ATP metabolism, and the respiratory chain,
including malfunction of the enzymes pyruvate
dehydrogenase phosphatase, pyruvate decarboxylase, cytochrome C oxidase, and NADHubiquinone reductase (see Chap. 33).

The principal source of lipid carbon in
brain is blood glucose

Carbohydrate intermediates and related metabolites, such as acetate (fatty acid and cholesterol), dihydroxyacetone phosphate (glycerol
phosphate), mannosamine, pyruv-ate (neuraminic acid), glucose-6-phosphate (inositol), galactose, and glucosamine, supply the building
blocks of the complex lipids (see Chap. 5).
NADPH is also necessary for the reductive synthesis of lipids. When a few polyunsaturated
fatty acids and sulfate are supplied, immature
brain slices readily form all the lipids of myelin
and cell membrane, using glucose as the only
substrate. Energy supply through the carbohydrate pathways in the form of ATP is also
required to supply nucleoside phosphates for
lipid assembly [8].

Carbohydrate utilization varies with the
brain's need for energy

The high functional requirement of nervous tissue for ,__ P is probably related to energy demands for transmitter synthesis, packaging, secretion, uptake, and sequestration; for ion
pumping to maintain ionic gradients; for intracellular transport; and for synthesis of complex
lipids and macromolecules in both neuronal and
glial cells. The manner in which metabolism is
coupled to function is conceptualized easily
from the discussion of the regulatory mechanisms that control carbohydrate metabolism
and can be illustrated by Na,K-ATPase, which
functions in the N a +-K + exchange pump so essential for maintaining electrolyte gradients (see
also Chap. 3). This enzyme is particularly active
in regions with high concentrations of synaptic
membranes, for example, gray matter and synaptosomes. The ADP released intracellularly is
an activating modulator for mitochondria and
several rate-limiting reactions: glycolytic (hexokinase, phosphofructokinase), Krebs cycle
(N AD-dependent isocitric dehydrogenase), and
glycogenolytic (phosphorylase). Changes accompanying the consequently increased metabolic flux lead to inhibition of other pathways,
such as that of glycogen synthesis and the pentose phosphate shunt, whereas lowered ""'P and
N ADPH levels inhibit various synthetic reactions. Because the products of reactions that
use ""'P are accelerators of reactions leading to
""'P formation, energy supply as ATP is regulated by utilization. The set-points of this regulation may be altered in certain toxic metabolic
states. Under many adverse conditions, for example, hypoxia, energy utilization is decreased
in brain, heart, and other tissues (see Chap. 40).
Although the linkage of neuronal function
to energy metabolism has been emphasized, it
should be pointed out that physiological failure
during hypoxia, ischemia, or hypoglycemia in
brain (and other tissues) begins before overall
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energy levels fall below those considered adequate to support function. Among the suggested
causes of dysfunction are defects in acetylcholine (see Pyruvate Dehydrogenase Complex,
above) and catecholamine synthesis. The affinity of tyrosine hydroxylase for oxygen is several
orders of magnitude less than that of the mitochondrial enzymes; this makes amine synthesis relatively more vulnerable to hypoxia.
Regional differences in metabolism add
a useful neurochemical dimension

There are two major techniques for studying regional metabolism. The first, developed by
Lowry and Passonneau [3], measures changes
in carbohydrate metabolites and energy cofactors during a few seconds of ischemia in microdissected samples and assumes that their
rates of change reflect those before ischemia.
The second (see Chap. 29) is based on the measurement of grain density by autoradiography
of freeze-dried sections after isotopically labeled deoxyglucose has been administered and
assumes instantaneous and sustained isotopic
equilibrium throughout brain tissue and plasma.
Other methods have been developed. Nuclear magnetic resonance (NMR) can be used
to quantitate separately the adenylate phosphates, creatine phosphate, sugar phosphates,
and phospholipids, although these molecules
cannot yet be used for anatomical mapping [13].
Chronically implanted surface coils in animal
brain have been used to determine local changes
in ,___ P during metabolic perturbations. Resonance detection of 13 C has made it possible to
measure glycogen in rat glycogen storage disease after glucose loading. ATP distribution can
be anatomically mapped in tissue sections by
bioluminescence based on enzyme-linked reactions.
Metabolic mapping, with even greater anatomic resolution in tissue sections than methods based on autoradiography, has been based
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on the histochemical assessment of phosphorylase and detection of glycogen (reversal of the
phosphorylase reaction). The normal glucose
flux estimated by the former method is usually
more than twice that of the deoxyglucose
method. Estimates based on the Lowry technique are increased by the stimulation resulting
from decapitation but are much closer to the
glucose consumption calculated from oxygen
consumption. Previous criticisms of the validity
of the deoxyglucose method [14] have been
amply and categorically refuted [15]. The deoxyglucose method of Sokoloff underestimates the
true flux in that equilibrium conditions are not
attained, but it gives accurate relative values in
different regions. It is thus a practical method
for comparing glucose phosphorylation in many
different regions simultaneously and under different conditions (see Chap. 29).
In general, those regions of brain with
higher metabolic requirements have both higher
enzyme activity in the glycolytic series and the
Krebs cycle and higher levels of respiration.
Several glycolytic and mitochondrial enzymes
are more active in regions with large numbers
of synaptic endings (neuropil) than in areas rich
in neuronal cell bodies. On the other hand, the
activity of glucose-6-phosphate dehydrogenase
(a rate-limiting enzyme of the pentose phosphate pathway) is high in myelinated fibers and
tends to vary with the degree of myelination.
Phosphofructokinase and phosphorylase are
distributed in a relatively constant ratio in different brain regions; this suggests a relationship
between glycolysis and glycogenolysis. Hexokinase distribution is more closely linked to mitochondrial enzymes than to glycolytic enzymes.
The oligodendroglia! cell that maintains
myelin in the CNS probably ranks, along with
the neuron and its processes, as having the highest known metabolic requirements. Although
the metabolism of neuronal terminals is high,
that of their cell bodies may actually be lower
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than that of astrocytes, which appear to have a
metabolic rate higher than early investigators
had suggested.
Because of its stratified structure, the
retina serves as a convenient model for
the study of regional metabolism

The rabbit retina is avascular and depends almost entirely on diffusion from choroidal capillaries. The primate retina, however, is vascularized from the vitreal surface as far as the
bipolar cell layer. The rabbit retina shows high
rates of glucose and oxygen consumption and
also of lactate formation. The high rate of aerobic lactate formation might be due to segregation of glycolytic and oxidative processes as
well as to the adaptation of the poorly vascularized inner layers to a relatively anoxic existence. The rod cell inner segment contains
packed mitochondria and has high levels of
mitochondrial enzymes and hexokinase. This
is the region closest to the choroidal nutrient
supply.
In the vascularized inner layers of the monkey retina, hexokinase activity is almost twice
that in the homologous layers of the rabbit retina. Several glycolytic enzymes, including
phosphofructokinase and glyceraldehyde phosphate dehydrogenase, as well as lactic dehydrogenase and glycogen phosphorylase, tend to
be higher toward the vitreous surface in rabbit
than in monkey retina. The total energy reserves (especially high glycogen levels) and lactate levels increase as the avascular vitreous
surface of the rabbit retina is approached. Malate dehydrogenase and N AD-dependent isocitrate dehydrogenase, the Krebs cycle enzymes,
vary with the relative density of mitochondria,
which is high in the layer of rod cell inner segments and in the synaptic layers. Data such as
these suggest that adaptive changes occur in
carbohydrate enzymes and metabolism and that
these changes are dependent on the local availability of substrates and oxygen. As in brain,

however, continued electrical responsiveness
of the retina depends on oxidative metabolism.

COMPOSITION OF FREE AMINO
ACID POOLS
The brain depends on transport of
essential amino acids from the blood

The carbon skeletons of certain amino acids,
termed "essential," cannot be synthesized at a
rate adequate to meet metabolic requirements.
These amino acids must be derived from the diet
and include arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Tyrosine is formed
in a single step from phenylalanine, and cysteine
takes its sulfur from methionine. Those amino
acids that can be made in the body of an animal
appear to be synthesized in the brain as well.
These "nonessential" amino acids are alanine,
aspartate, and glutamate made by transaminations of a-keto acids; proline derived from glutamate; serine derived from 3-phosphoglycerate
or from glycine; serine made from glycine plus
tetrahydrofolate; glutamine from ammonia and
glutamate; and asparagine from transamidation
of aspartate (see Chaps. 15 and 38 for specific
reactions).
Ammonia is taken up by brain when circulating ammonia levels are increased either experimentally or when liver function is impaired.
Ammonia uptake from normal circulatory ammonia levels probably is sufficient to maintain
the brain in nitrogen balance, although the proportion of nitrogen supplied as ammonia to that
available as preformed amino acids is not well
established.
Essential free amino acids in brain are
present at low levels; their content in protein
components is several hundred times higher.
Because of this concentration difference, an incremental growth of less than 1 percent in brain
protein would exhaust the available free amino
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acid content of the brain, were it not replenished
from the circulation.
Neurochemists noted early that the composition of the free amino acid pool in the brain
differs from that of other tissues; the biggest
difference is the relatively high content of glutamate and related amino acids, including aspartate, glutamine, and GABA. Together they
make up more than half the total free amino acid
content in brain.

ally a few hours. Since the amount of the amino
acid in protein is much larger than its free concentration, when a labeled amino acid is given,
most of the label will be in the protein-bound
form in a short time.

Glutamate uniquely supports the
respiration of incubated slices of brain

In general, three groups can be distinguished:
(1) the essential amino acids, which are present
at fairly low levels, close to those in plasma; (2)
the nonessential amino acids, which are present
at concentrations several times higher than the
essential ones; and (3) compounds present in
brain but absent or at very low levels in most
other organs, such as GABA and N-acetylaspartate [ 17].
The composition of the free amino acid
pool, as shown in Table 1, is similar in most
species [18]. The amino acid level is much lower
in CSF than in brain, although the amino acid
concentration in brain interstitial fluid may be
similar to that of CSF. CSF amino acid levels
are also lower than those in plasma. The amino
acid composition of CSF is not parallel to that
of brain; for example, there are high glutamine
and low glutamate levels in the CSF, and the
brain/CSF concentration ratio for glutamate is
approximately 800. The free pool in brain also
does not reflect the amino acid composition of
the cerebral proteins. The amino acids are
present at much higher levels in the proteinbound than in the free form. The concentration
ratio of protein-bound, to free, amino acids in
brain varies from 10 for glutamic acid to 1,800
for isoleucine. The amino acids present at high
levels (glutamate, taurine, GABA, and glycine)
are the most active pharmacologically. The
amino acids are not all evenly distributed in the
brain; for example, taurine and glutamic acid
are much lower, and glycine is much higher in
the midbrain and pons than in other areas. There

Radioactivity rapidly accumulates in brain glutamate after the administration of radioactive
glucose. Very rapid isotopic equilibration occurs via the Krebs cycle and oxoglutarate-glutamate amino transfer. For net synthesis of glutamate, C02 fixation must occur, and this
process has been shown to be present in brain.
:Vthough many studies have measured changes
1n glutamate under hypoglycemic and ischemic
conditions, the r·ole of glutamate in energy production in the brain has not been clearly established. This concept led to unsuccessful trials
of glutamate feeding as a treatment for mental
illness. It was demonstrated that such feeding
is unable to elevate cerebral glutamate levels
because of an effective blood-brain barrier to
the entry of this amino acid. Both under normal
conditions and in acute ammonia toxicity, the
conversion of glutamate to glutamine is the main
form of removal of cerebral ammonia. This glutamine is formed from the small, rapidly turning-over glutamate pool. There seems to be little
capacity for adaptation to hyperammonemia in
the brain [16].

Active protein metabolism in the brain
results in a high rate of exchange
between free and protein-bound amino
acids
The half-life of free amino acids through exchange to protein-bound forms in brain is usu-

The content of free amino acids in the
brain is maintained at fairly constant
levels
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TABLE 1.

Levels of free amino acids and related substancesa
Brain

Glutamic acid
Taurine
N-Acetylaspartate
Glutamine
Aspartic acid
-y-Aminobutyric acid
Glycine
Alanine
Serine
Threonine
Lysine
Arginine
Histidine
Valine
Leucine
Isoleucine
Phenylalanine
Tyrosine
Proline
Methionine
Ornithine
Phosphoethanolam i ne
Cystathionine
Homocarnosine
Glutathione

Human

Cat

Rat

Carp

Monkey

Brain

CSF

Plasma

600
130
600
400
150
88
62

1,160
660
560
450
260
230
68
65
98
66
21
11
5
7
5
2
5
7
8
4
2
200
2
6
260

550
480
80
770
350

1,100
180

600
93
490
580
96
42
40
25
44
27
12
10
9
13
7
3
5
6
10
3
3
110
200
23
200

0.8
0.6

2
6
0
60
0.2
0
22
35
11
14
19

so
52
17
10
9
13
13
8
5
4
5
13
1
4
93
21
0.4
170

62
66
33
36
34
14
36
15
22
13
13
9
12
7
62
32

540
240
94
48
25
45
13
10
10
8
4
4
2
4
4
7
2
3
150
4
59
220

so
0.02
0.7
2.6
2.5
2.5
2.1
1.8
1.3
1.6
1.1
0.4
0.8
0.8
0.3
0.6

8
9
23
12
6
5
5
18
2
5
0.2
0

0.3

Values presented are averages from many publications and are expressed as ~mol amino acid/100 g brain, or 100 ml
CSF or plasma.

a

are further indications of differences among various cells, but they are not easy to establish.
The methods for separation and isolation of
cells and of particulate fractions such as synaptosomes include procedures that result in
losses or redistribution of the soluble amino
acids. Most amino acids are stable; since the
formation of GABA from glutamic acid is very
rapid, GABA levels determined postmortem are
not accurate. With sensitive techniques, the distribution of the nonessential amino acids has
been measured in as many as 50 different brain
structures, and concentration ratios between
the highest and the lowest levels are 3 to 10, but
with the majority of areas being close. Levels
in synaptosomes are similar to those measured

for whole brain. Although some attempts have
been made with nonaqueous separation methods or microdialysis to measure the extracellular amino acid levels, the available data are
difficult to interpret. (The physiological activity
of amino acids is further discussed in Chap. 15;
regional differences in transport are discussed
later.)
Less is known about the distribution of certain peptides, mainly because methods are not
as well developed for their separation and detection, and they are usually present at very low
levels. Only a few peptides, such as glutathione,
are present at high levels in the brain. Interest
in this class of compounds is great because of
their physiological activity (see Chap. 14). It is

"
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likely that a large number of pep tides, still unidentified, are present in the brain. There are
indications that a number of peptides are
present exclusively in brain. Many -y-glutamyl
peptides are found, including -y-glutamyl derivatives of glutamate, glutamine, glycine, alanine,
~-aminoisobutyric acid, serine, and valine.
These peptides are present at levels of 10 to 700
mg/g fresh tissue, and they may be formed by
transpeptidation reactions from glutathione. Nacetyl-aspartylglutamate is present in fairly
large amounts (----10-30 mg/100 g fresh brain).
No function has been attributed to this peptide,
but it is known that it forms theN-terminal sequence of the actin molecule in muscle, and it
may play a similar role in one or more brain
proteins.
Homocarnosine and homoanserine, two
peptides of histidine, are also unique to brain.
Homocamosine is -y-aminobutyrylhistidine, the
homolog of the long-known muscle constituent,
~-alanyl-L-histidine (carnosine). Homoanserine, the -y-aminobutyryl homolog of anserine (~
alanyl-1-methyl-L-histidine) is also present.
These histidine peptides are at much higher levels in this tissue than are their more widely distributed relatives carnosine and anserine. Carnosine is restricted primarily to the olfactory
areas of the brain; in the rest of the brain, mainly
homocarnosine is present. Since destruction of
nasal epithelium results in a marked decrease
of olfactory bulb carnosine, this compound
might have a role in olfaction.

The composition of the free amino acid
pool in peripheral nerve is different
from that in the brain

Most amino acids in mammalian nerve are lower
than in brain. GABA is almost absent in vertebrate peripheral nerve. In some crustacean
species, a few specific compounds, such as aspartate, glycine, and alanine, are at very high
levels. In other species the levels of com-

pounds, such as taurine, are 10 to 100 times
higher in peripheral nerve than in brain.
Components of the free amino acid
pool undergo complex changes during
the maturation of the brain

These changes are not strictly parallel in all
brain regions; some are illustrated in Table 2.
Quantitatively, the greatest changes are a decrease in taurine and an increase in glutamate.
These changes are gradual compared with the
rapid decrease in alanine near the time of birth.
Although such changes indicate developmental
changes in metabolism (in the relative rates of
various metabolic pathways), the connection
between substrate levels and metabolism is not
clear. It is tempting to theorize that the decrease
in essential amino acids parallels the decrease
in the rate of protein turnover, for example, but
one does not necessarily lead to the other. Although changes in amino acid levels, after lowprotein diets, result in changes in protein metabolism in a number of organs, such as muscle
and liver, brain protein metabolism seems to
be resistant. Of special importance are alteraTABLE 2.

Changes in amino acid levels during
developmenta

Taurine
Glutamate
Aspartate
Threonine
Proline
Glycine
Alanine
Leucine
Tyrosine
Phenylalanine
')'-Aminobutyric
acid
Arginine

Fetal
(15 day)

Newborn
(1 day)

Adult

14
7.5
2.4
4.3
0.89
2.26
5.08
0.53
0.24
0.24
0.50

16
5.0
2.3
0.90
0.57
2.30
0.80
0.18
0.20
0.13
1.62

8.0
12
3.8
0.56
0.15
1.27
0.56
0.06
0.08
0.07
2.37

0.45

0.14

0.11

Values are from mouse brain, expressed as f.LmOI amino
acid/g brain tissue.

a
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tions in the levels of amino acids, such as tyrosine and tryptophan, that serve as precursors
of neurotransmitters. Developmental changes
in GABA levels may influence seizure sensitivity, and region-specific decreases in GABA levels have been reported [18].

Brain amino acids are in dynamic
equilibrium, undergoing rapid
metabolism and rapid exchange with
plasma amino acids
Flux of the essential amino acids is especially
high, with a half-life (time for half of the brain
content to be exchanged) of a few minutes. Isotopic equilibrium is reached rapidly; this indicates that amino acids do not have an inaccessible, nonexchangeable fraction, although they
remain relatively constant in level, as discussed
above. Their distribution is heterogeneous:
there are differences in transport rate, metabolic rate, and metabolic use in various compartments-cellular, subcellular, or regionalreflecting the enzymatic, morphological, and
functional heterogeneity of the brain. As discussed in Chapter 30, the carriers responsible
for transporting the amino acid classes between
blood and brain are close to saturation, and
therefore the selective increase in a single
amino acid alters the transport of other members of its class [19].
Although a general increase (for example,
after a meal) of all related amino acids does not
increase their brain levels, a selective increase
in the blood level of an amino acid that is a
neurotransmitter precursor can result in an increase of the cerebral level of both that amino
acid and its product, the neurotransmitter. For
example, the increase in plasma tryptophan
after meals is not reflected in brain, because
other related amino acids also increase in
plasma, competing for the same transport system and mutually inhibiting one another's uptake. However, a selective increase of tryptophan, especially when accompanied by a

decrease in the level of competing amino acids,
increases the cerebral levels of tryptophan and
its metabolic products, such as serotonin [20].
Although variations in the level of essential
amino acids in the brain may occur under special or extreme conditions, the penetration of
nonessential amino acids into brain is much
slower, and no change in brain content occurs,
even during large blood level alterations of these
compounds.
In severe malnutrition, the changes of the
brain amino acid pools are rather specific: There
is a large increase in histidine and homocarnosine [21], whereas some amino acids, such as
valine, serine, and aspartate, decrease. In insulin hypoglycemia, the major changes are decreases of nonessential amino acids; most likely
this reflects changes in the activity of the citric
acid cycle. Hyperthyroidism increases most of
the nonessential amino acids. In general, relatively small changes in the reaction rates involved in carbohydrate or energy metabolism
do not affect the levels of cerebral amino acids,
whereas major changes do, with primarily glutamate, aspartate, alanine, and GABA affected.
In ischemia, hypoxia, and hypothermia, glutamate and aspartate decrease and GABA increases. Similar changes may be found in hibernating animals; on arousal, levels return to
normal.
The changes are somewhat different in convulsions. In human epileptogenic brain tissue,
the most consistent changes reported were decreases in glutamate and taurine and an increase
in glycine. These changes were localized in
areas of pathological changes; in surrounding
areas, aspartate and GABA levels were also reduced [22]. Such changes could be reproduced
in experimentally induced convulsive states. On
the administration of taurine, amino acid levels
tended to return to normal. In induced convulsions, such changes also depend on the convulsant used: Pentamethylenetetrazole causes
an increase in alanine (interference with the
entry of pyruvate into the citric acid cycle); in-
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hibitors of glutamic acid dehydrogenase (GAD)
result in increased levels of glutamate.
Drugs have also been reported to affect the
levels of nonessential amino acids. Chlorpromazine can lower glutamate, aspartate, and
GABA; drugs, such as reserpine and 6-hydroxydopamine, that alter catecholamine metabolism have similar effects. Ethanol is reported to
reduce GABA levels [18]. Some anticonvulsant
drugs increase GABA levels, whereas some that
inhibit GABA formation are convulsants [23].
Elevated levels of circulating ammonia are
known to cause large increases in the level of
brain glutamine. Loss of liver function in humans, which prevents the normal detoxification
of ammonia, leads to ammoniagenic coma and
increased levels of glutamine in the CSF. It has
been suggested that this causes depletion of
Krebs cycle intermediates in brain, thus leading
to decreased oxidation and energy production;
however, the demonstration that ammonia stimulates the flux of glucose through the Krebs
cycle in brain contradicts this suggestion.

SPECIFIC AMINO ACID TRANSPORT
SYSTEMS
The existence of transport classes is not specific
for the brain, and many of the classes found in
brain have the properties of these systems in
other organs. In brain cells more than ten transport classes can be identified, with some overlap. Some of these have not yet been observed
in other tissues. Some are specific for one type
of amino acid: small neutral, large neutral,
acidic, or basic. Others are fairly specific for a
single amino acid: glycine, proline, GABA,
taurine, or lysine [24]. In vivo, the transport by
brain capillaries appears to utilize only three
classes-large neutral, large basic, and acidic
(see Chaps. 15 and 30). Diffusion of the nontransported amino acids into brain is a much
slower process than transport, and it can occur
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only in the direction from higher to lower concentration. The high rate of cellular transport
for the nonessential amino acids, combined with
low capillary transport of the same compounds,
is specific for brain.
There is overlap among the classes because
some amino acids have an affinity for more than
one carrier. In substrate specificity, the transport classes in brain are similar, but not identical, to those described in other systems.
In addition to the transport classes discussed above, which have relatively low affinity, amino acid transport classes with high affinity and high substrate specificity have been
described in brain. These classes have been
found primarily in synaptosomal preparations.
It was proposed that the low-affinity (Km = 10 - 3
M), more generally distributed transport systems serve metabolic functions; the high-affinity (Km = 10 - 5 M) systems remove the physiologically active (neurotransmitter) amino
acids. This high-affinity transport was suggested as another criterion for assignment of
neurotransmitter function. It was found for a
number of amino acids in the brain, including
glutamate, aspartate, GABA, glycine, proline,
tryptophan, and taurine, each of which is also
a substrate for low-affinity transport. Although
the suggestion of high-affinity transport as a
special mechanism for the removal of neurotransmitters in instances where metabolic inactivation is not sufficient is very attractive,
there are indications of other functions for this
process. The distribution of high-affinity systems does not seem to be highly specific; for
example, high-affinity tryptophan uptake does
not follow the serotonergic system or serotonin
receptor binding, and a number of high-affinity
systems, such as that for taurine, are present in
glial and in neuronal cells. Furthermore, highaffinity uptake is found for such nonneurotransmitter amino acids as leucine and in other tissues as liver and heart. In spite of these findings
indicating possible additional roles for the highaffinity uptake, the fact that these systems for
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the neurotransmitter amino acids are present
primarily in synaptic or postsynaptic structures,
and there they are the predominant transport
system, indicates that they are likely to be a
mechanism for amino acid removal.
Stereospecificity is not absolute: D amino
acids are transported in most cases, but at considerably lower levels than are the L isomers.
Despite this, some D amino acids can penetrate
the brain. Although their uptake is slower, so
is their exit, thus leading to slow accumulation.
This again illustrates that both uptake and exit
influence the levels of compounds. The amino
acid concentration within brain cells is generally
higher than in brain interstitial fluid. This indicates that transport into the cells occurs
against a concentration gradient. Such transport
requires energy. The primary source of the energy that fuels active amino acid transport is not
known. Inhibitors of metabolic energy also inhibit amino acid uptake, and in many cases, but
not all, the decrease in ATP levels is accompanied by a decrease in uptake. Such inhibition,
however, may be indirect.
There is evidence that N a+ electrochemical gradients may be a driving force for transport of selected amino acids. Not all compounds
show the same dependence on N a + : Diamine
uptake is independent, and basic amino acid uptake is only partially dependent on N a + levels.
Thus, lowering N a + does not affect all amino
acids to the same degree. The N a + dependence
of high-affinity uptake appears to be greater
than that of low-affinity uptake. The Na + dependence of low-affinity systems is variable,
those participating more in exchange having
lower or no Na + dependence. Although other
ions (probably K +, possibly Ca2 +) may also influence transport, N a + seems to be a primary
factor. The ion co transport ratio was measured
in GABA uptake in various neuronal, glial, and
synaptosomal preparations, and some variations in the GABA-Na + cotransport coupling
ratio were found, with 1 : 1 in astrocytes and 1 : 3

in neurons. The fact that several ratios were
found indicates that GABA transport properties
are modulated in different systems, but also that
more than one GABA transport system may be
present.
Transport of amino acids in brain
changes during development

The composition of the brain, including the free
amino acid pool, undergoes large changes during development as described earlier (Table 2).
Permeability is generally greater in young than
in adult brain. The developing brain therefore
is not as well protected as the mature brain from
fluctuations in plasma metabolite levels and
from foreign substances, such as drugs. Although developmental changes in the free pool
and in permeability to amino acids have been
studied in detail, changes in amino acid transport are not as well documented.
Elevation of most amino acids in plasma
causes a greater elevation of levels in brain in
young, compared with adult, animals; however,
barriers and transport processes are not entirely
absent in the immature brain. For example,
amino acid levels in fetal brain differ from those
in fetal blood. As in adults, the barrier to nonessential amino acid penetration into the young
brain is greater than the barrier to essential
amino acids. Many transport processes develop
rapidly and are present at early developmental
stages. The transport systems for neurotransmitters develop somewhat later. Transport
properties, such as apparent affinity (Km), usually show no developmental alterations; GABA
is an exception to this rule, with one GABA
transport system present in immature cells that
disappears during development. Capillary
transport activity, like capillary permeability, is
greater in the immature brain, perhaps reflecting the increased need for amino acid supply
during growth.
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Distribution, especially of nonessential
amino acids, is heterogeneous within
the brain

Only gross distribution has been studied, but
there are indications that the amino acid pool
in neurons is different from that in glia and that
additional differences exist between nuclear
and mitochondrial compartments. Lysosomes,
in which protein degradation takes place, and
the nerve-ending region, where release andremoval of neurotransmitter amino acids take
place, also represent special compartments.
The indications are that GABA transport and
glutamine transport in neurons are different
from that in glial cells. Possibly, high-affinity
glutamate uptake is present mostly in the glutamatergic cells or in glia near such cells.
Perhaps the most heterogeneous distribution of transport systems is represented by the
high-affinity transport in synaptosomes. Synaptosomes containing the high-affinity glutamate system are distinct from those containing
the GABA system; and synaptosomes from
spinal cord, but not those from brain, contain
the glycine system [25].
Amino acid transport may influence
brain development

It seems that the period most sensitive to amino
acid transport occurs when cell division takes
place; this is also the period during which recovery can occur. Protein deficiency throughout the active mitotic period results in a permanent decrease in brain cell number and
protein content [26]. Learning deficiencies are
also seen; such deficiencies may carry over to
the progeny, even if they are all well-nourished
(see also Chap. 38).
In contrast, in adult protein deficiency,
brain protein content is maintained despite the
decrease of proteins in most other organs. This
is thought to be the consequence of a more ac-
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tive amino acid transport in the adult brain that
maintains the free amino acid pool to a greater
degree than in other organs [17]. Pathological
changes in protein metabolism could alter the
free amino acid pool, since the major portion of
amino acids is protein bound; for example, a net
protein breakdown of 1 percent would increase
most amino acids severalfold. An important,
but still undecided, question concerns what effect an altered amino acid pool has on brain
function. Brain protein synthesis in general is
not sensitive to alteration of amino acid levels,
and it is most likely that changes that alter neurotransmitters are of greater functional importance.
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